Navigation Links
Endologix Receives Nasdaq Letter on Director Independence
Date:6/12/2009

IRVINE, Calif., June 12 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, today announced that on June 12, 2009, the Company received written notification from Nasdaq that the Company was no longer in compliance with Marketplace Rule 4350(c), which addresses independent director requirements.

In order to meet the requirements of this rule, the Company must maintain a board which is comprised of a majority of independent directors. Following the Company's Annual Meeting of Shareholders on June 11th, 2009, the current board composition reflects three independent and three non-independent directors. Consistent with Marketplace Rule 4350(c) (1), Nasdaq will provide the company a cure period in order to regain compliance until the earlier of the Company's next annual shareholders' meeting or June 11, 2010.

The Company is currently engaged in a search for a new independent director and fully expects to fulfill Nasdaq's independent director requirements within the allotted cure period.

The Company must submit to Nasdaq documentation, including biographies of any new directors, evidencing compliance within the allotted cure period. In the event the Company does not regain compliance within this cure period, Nasdaq rules require Staff to provide written notification to the Company that its securities will be delisted. At that time, the Company may appeal the delisting determination to a Listing Qualifications Panel.

About Endologix

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's flagship product is the Powerlink(R) System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's Web site at www.endologix.com.

Except for historical information contained herein, this news release contains forward-looking statements, specifically with respect to the fulfillment of Nasdaq independent director requirements, which are necessarily subject to risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Endologix. The Company undertakes no obligation to update its forward looking statements. Please refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and the Company's other filings with the Securities and Exchange Commission, for more detailed information regarding risks and other factors that may cause actual results to differ materially from those expressed or implied.

    COMPANY CONTACT:                     INVESTOR CONTACTS:
    Endologix, Inc.                      The Ruth Group
    John McDermott, CEO                  Nick Laudico (646) 536-7030
    (949) 595-7200                       Zack Kubow (646) 536-7020
    www.endologix.com


'/>"/>
SOURCE Endologix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Endologix Announces Full Commercial Launch of IntuiTrak Express Delivery System
2. Anderson ED Team Receives Pinnacle Award for Excellence in Customer Service
3. Western Governors University Nursing Education Program Receives $500,000 Grant from the Texas Workforce Commission
4. Oncology Program at Texas Health Dallas Receives Outstanding Achievement Award
5. SeprOx Receives Texas Emerging Technology Fund Award
6. SHPS Receives Re-Accreditation from URAC for Multiple Health Management Programs
7. Herley Receives a $1.2 Million Contract Award for Complex Integrated Microwave Assemblies for U.S. Electronic Attack Aircraft
8. Elder Care Expert Doctor Marion Receives Accolades from Lehman College, Mature Market Resource Center in Same Week
9. Medifocus, Inc. receives Authorization Approval from Health Canada to launch its pivotal Phase III clinical study of focused microwave heating for treatment of breast cancer in Canada
10. Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance
11. MedApps Receives FDA Clearance on a New Way to Bring Cost-Effective Remote Health Monitoring to More People
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Aliso Viejo, California (PRWEB) , ... June 27, 2016 , ... ... that are fully customizable inside of Final Cut Pro X," said Christina Austin - ... with another unique style. Final Cut Pro X users can now reveal ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... its strategic partnership with Connance, a healthcare industry leader providing predictive analytics ... proprietary technology combine to provide health systems, hospitals and ambulatory surgical centers ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating ... Millions of individuals in the United States and Canada wear eyeglasses. Once considered to ... correct vision and make a fashion statement. Even celebrities use glasses as a way ...
(Date:6/26/2016)... Battle Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... abuse, joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table ... held in honor of the city’s history as home to some of the world’s ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
Breaking Medicine Technology: